In vitro diagnostics company Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced on Monday that the US Food and Drug Administration granted 510(k) clearance for its Accelerate Arc system and BC kit.
This platform automates positive blood culture sample preparation for use with Bruker's MALDI Biotyper CA System and Sepsityper software.
Designed for clinical labs, the system streamlines microbial identification, bypassing the need for overnight culture methods. This reduces wait times for results, crucial in sepsis treatment. Accelerate Arc leverages Bruker's reference library for rapid identification, complementing the company's future WAVE system for antibiotic susceptibility testing.
Faster results improve patient outcomes, lower antimicrobial resistance and reduce hospital costs. Additionally, Accelerate Arc replaces overnight subculture and labour-intensive Laboratory Developed Tests, meeting regulatory pressures for FDA-cleared devices.
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes